In particular, BLU-667: (1) demonstrated increased efficacy over approved MKIs against oncogenic RET variants in vitro; (2) inhibited growth of NSCLC and thyroid cancer xenografts; and (3) in first testing in patients with RET-altered NSCLC and MTC, significantly inhibited RET pathways and induced durable clinical responses without notable off-target toxicity[111]. Here, RET is linked to medullary thyroid gland carcinoma.